Your browser doesn't support javascript.
loading
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function.
Hiraoka, Atsushi; Kumada, Takashi; Tada, Toshifumi; Hirooka, Masashi; Kariyama, Kazuya; Tani, Joji; Atsukawa, Masanori; Takaguchi, Koichi; Itobayashi, Ei; Fukunishi, Shinya; Tsuji, Kunihiko; Ishikawa, Toru; Tajiri, Kazuto; Ochi, Hironori; Yasuda, Satoshi; Toyoda, Hidenori; Ogawa, Chikara; Nishimura, Takashi; Hatanaka, Takeshi; Kakizaki, Satoru; Shimada, Noritomo; Kawata, Kazuhito; Naganuma, Atsushi; Kosaka, Hisashi; Matono, Tomomitsu; Kuroda, Hidekatsu; Yata, Yutaka; Ohama, Hideko; Tada, Fujimasa; Nouso, Kazuhiro; Morishita, Asahiro; Tsutsui, Akemi; Nagano, Takuya; Itokawa, Norio; Okubo, Tomomi; Arai, Taeang; Yokohama, Keisuke; Imai, Michitaka; Koizumi, Yohei; Nakamura, Shinichiro; Iijima, Hiroko; Kaibori, Masaki; Hiasa, Yoichi.
  • Hiraoka A; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
  • Kumada T; Department of Nursing, Gifu Kyoritsu University, Ogaki, Japan.
  • Tada T; Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
  • Hirooka M; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
  • Kariyama K; Department of Hepatology, Okayama City Hospital, Okayama, Japan.
  • Tani J; Department of Gastroenterology and Hepatology, Kagawa University, Takamatsu, Japan.
  • Atsukawa M; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
  • Takaguchi K; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
  • Itobayashi E; Department of Gastroenterology, Asahi General Hospital, Asahi, Japan.
  • Fukunishi S; Department of Gastroenterology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
  • Tsuji K; Center of Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.
  • Ishikawa T; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
  • Tajiri K; Department of Gastroenterology, Toyama University Hospital, Toyama, Japan.
  • Ochi H; Hepato-biliary Center, Japanese Red Cross Matsuyama Hospital, Matsuyama, Japan.
  • Yasuda S; Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
  • Toyoda H; Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
  • Ogawa C; Department of Gastroenterology, Japanese Red Cross Takamatsu Hospital, Takamatsu, Japan.
  • Nishimura T; Department of Gastroenterology and Hepatology, Hyogo Medical University, Nishinomiya, Japan.
  • Hatanaka T; Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Maebashi, Japan.
  • Kakizaki S; Department of Clinical Research, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan.
  • Shimada N; Division of Gastroenterology and Hepatology, Otakanomori Hospital, Kashiwa, Japan.
  • Kawata K; Hepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Naganuma A; Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan.
  • Kosaka H; Department of Surgery, Kansai Medical University, Hirakata, Japan.
  • Matono T; Department of Hepatology, St. Mary's Hospital, Himeji, Japan.
  • Kuroda H; Division of Hepatology, Department of Internal Medicine, Iwate Medical University, School of Medicine, Morioka, Japan.
  • Yata Y; Department of Gastroenterology, Hanwa Memorial Hospital, Osaka, Japan.
  • Ohama H; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
  • Tada F; Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
  • Nouso K; Department of Hepatology, Okayama City Hospital, Okayama, Japan.
  • Morishita A; Department of Gastroenterology and Hepatology, Kagawa University, Takamatsu, Japan.
  • Tsutsui A; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
  • Nagano T; Department of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
  • Itokawa N; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
  • Okubo T; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
  • Arai T; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
  • Yokohama K; Department of Gastroenterology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
  • Imai M; Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
  • Koizumi Y; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
  • Nakamura S; Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
  • Iijima H; Department of Gastroenterology and Hepatology, Hyogo Medical University, Nishinomiya, Japan.
  • Kaibori M; Department of Surgery, Kansai Medical University, Hirakata, Japan.
  • Hiasa Y; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
Oncology ; 101(10): 624-633, 2023.
Article en En | MEDLINE | ID: mdl-37307798
ABSTRACT

INTRODUCTION:

Lack of an established methodology for post-progression systemic treatment following atezolizumab plus bevacizumab (Atez/Bev) administration is an important clinical issue. The present study aimed to elucidate the potential of lenvatinib as a second-line treatment option after Atez/Bev failure.

METHODS:

From 2020 to 2022, 101 patients who received lenvatinib as second-line treatment were enrolled (median 72 years, males 77, Child-Pugh A 82, BCLC-ABCD = 135614), while 29 treated with another molecular targeting agent (MTA) during the period as second-line treatment were enrolled as controls. The therapeutic efficacy of lenvatinib given as second-line treatment was retrospectively evaluated.

RESULTS:

Median progression-free survival/median overall survival for all patients was 4.4/15.7 months and for those with Child-Pugh A was 4.7 months/not-reached. When prognosis was compared with patients who received another MTA, there was no significant difference for PFS (3.5 months, p = 0.557) or OS (13.6 months, p = 0.992), and also no significant differences regarding clinical background factors. mRECIST findings showed that objective response and disease control rates in patients treated with lenvatinib were 23.9% and 70.4%, respectively (CRPRSDPD = 3143321), while those shown by RECIST, ver. 1.1, were 15.4% and 66.2%, respectively (CRPRSDPD = 1103624). Adverse events (any grade ≥10%) were appetite loss (26.7%) (grade 123 = 21510), general fatigue (21.8%) (grade 123 = 3136), protein in urine (16.8%) (grade 123 = 0413), and hypertension (13.9%) (grade 123 = 185).

CONCLUSION:

Although lenvatinib treatment might not provide a pseudo-combination immunotherapy effect following Atez/Bev failure, lenvatinib when used as second-line treatment after Atez/Bev failure might be expected to be comparable as compared to its use as first-line treatment.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudio: Observational_studies / Prognostic_studies Límite: Humans / Male Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudio: Observational_studies / Prognostic_studies Límite: Humans / Male Idioma: En Año: 2023 Tipo del documento: Article